Three piglets standing on an orange slatted floor in an enclosure, with one playing with a hanging yellow toy and a large red ball visible in the foreground.

Revivicor | United Therapeutics

0:00

[ the problem ]

Over a million people in the United States need a heart or kidney. The gap between available organs and how many actually get transplanted is one of the most urgent problems in modern medicine. Revivicor has spent the last 25 years working on the answer.

United Therapeutics needed a piece to highlight the cutting-edge science that's been taking place at Revivicor for decades.

Revivicor is made up of a team of scientists, molecular biologists, regulatory staff and farm workers who have committed their careers to technology most people are only now hearing about. Dr. David Ayares is one of them. He was part of the group that cloned Dolly the sheep. Today he oversees animal research at Revivicor in Blacksburg, Virginia, where genetically modified pigs are being raised as the progenitors for clinical trials that could reshape transplant medicine entirely.

[ our solution ]

Biotech companies are carrying some of the most important scientific narratives of our time and most of them are still leading with slide decks. That's a particular problem in investor relations, where the difference between interest and conviction often comes down to whether someone can see the work, understand the people behind it, and believe in the mission. A 25-year commitment is hard to feel in a spreadsheet. It's easy to feel in a film.

We produced a documentary and a full suite of stills that put Dr. Ayares and the Revivicor team at the center of the story, from the science of somatic cell nuclear transfer to the morning routine of saying hello to the pigs. The content went directly into investor relations presentations and marketing material to prove that the people are as serious as the science.